Related Experiment Video

Updated: Apr 26, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies

P Vanichakarn, J Hwa, J Stitham1

  • 1Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, 300 George Street, Room 793, New Haven, CT 06511, USA. jeremiah.stitham@yale.edu.

Current Molecular Medicine
|August 12, 2014
PubMed

Insights

Personalized medicine using cardiovascular pharmacogenetics can improve treatment for hypertension and hyperlipidemia. Identifying genetic biomarkers helps optimize drug selection and dosing for better patient outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenetics
  • Clinical Pharmacology

Background:

  • Clinical guidelines emphasize preventing cardiovascular disease (CVD) by managing hypertension and hyperlipidemia.
  • Pharmacotherapy is crucial but often limited by patient response variability.
  • Hypertension and hyperlipidemia significantly contribute to CVD development and progression.

Purpose of the Study:

  • To explore the role of personalized pharmacotherapy in CVD prevention.
  • To investigate the potential of cardiovascular pharmacogenetics in optimizing treatment.
  • To identify genetic biomarkers for improved drug response and disease susceptibility.

Main Methods:

  • Review of current clinical management guidelines for hypertension and hyperlipidemia.
  • Analysis of the contribution of hypertension and hyperlipidemia to cardiovascular disease.
  • Exploration of advancements in cardiovascular pharmacogenetics for personalized medicine.

Main Results:

  • Many patients do not achieve therapeutic goals due to variable drug responses.
  • Personalized pharmacotherapy is essential for effective CVD risk factor control.
  • Cardiovascular pharmacogenetics offers a pathway to identify genetic biomarkers for tailored treatment.

Conclusions:

  • Individualized approaches to pharmacotherapy and disease prevention are critical.
  • Identifying genetic biomarkers can lead to informed drug selection and dosing.
  • Advancements in pharmacogenetics promise improved patient care for hypertension and hyperlipidemia.

More Related Videos

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
241
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
135